IFS Securities Names David Bouchey, Ph.D., Head of Healthcare Research

Atlanta, Georgia--(Newsfile Corp. - December 31, 2015) - IFS Securities (IFS) announces today the appointment of David Bouchey, Ph.D., as Head of Healthcare Research. In this role Dr. Bouchey will focus on Bio Pharmaceuticals.

He brings 15 years of research analyst experience in small, mid cap and large emerging therapeutics and medical device coverage to IFS.  Dr. Bouchey specializes in providing financial, business and clinical development services with expertise in identifying and evaluating emerging biotechnology and pharmaceutical companies. He has been recognized for his research analysis and financial modeling by both Institutional Investor Magazine and Starmine Analyst Ranking Service. 

"We are proud to have Dr. David Bouchey join our team. His knowledge and experience will be a valuable asset to IFS and our clients," Alex McKenzie, President and CEO, said.

Dr. Bouchey obtained a B.S. in Microbiology and Pubic Health from Michigan State University; an M.S in Virology and an M.B.A in Finance and Monetary Economics from the University of Kentucky; and his Ph.D. in Cell and Molecular Biology from the University of Virginia.

IFS has two platforms, an independent advisor network that caters to retail clients throughout the U.S. and a capital markets division for institutional and corporate clients. 

About IFS Securities
IFS Securities, Inc., is a full-service independent broker-dealer that understands retail and wholesale advisory networks as well as global capital markets. IFS offers financial advisory; brokerage support; equity research; fixed income and equity trading; and investment banking services. Based in Atlanta, IFS Securities has 123 registered reps in 32 offices in 17 states and Puerto Rico and is a member of FINRA, MSRB and SIPC. For more information about IFS Securities, visit the website at www.ifssecurities.com or call 404-382-5223.

Media Contact:
Juliann Kaiser
Kaiser Marketing Group
770-643-0615
jkaiser@kaisermarketinggroup.com

This press release is for informational purposes only and is not an offer to buy or the solicitation of an offer to sell any securities by IFS Securities.

# # #